Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 401–500 of 1,000
Remyelination of optic nerve lesions: spatial and temporal factors
Klistorner, A. I., Arvind, H., Garrick, R., Yiannikas, C., Paine, M., & Graham, S. L. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510371408 · Cited by 48
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination
Mierzwa, A. J., Zhou, Y.-X., Hibbits, N., Vana, A. C., & Armstrong, R. C. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.05.010 · Cited by 42
“Modifying inhibitory signals in lesion areas could potentially enhance functional recovery in MS patients by improving the remyelination capacity of immature OLCs that persist in MS lesions [4,9].”
Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination
Watzlawik, J. O., Warrington, A. E., & Rodriguez, M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.13 · Cited by 52
Zhang, M., Zhan, X. L., Ma, Z. Y., Chen, X. S., Cai, Q. Y., & Yao, Z. X. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370214565975 · Cited by 42
Mozafari, S., Javan, M., Sherafat, M. A., Mirnajafi-Zadeh, J., Heibatollahi, M., Pour-Beiranvand, S., Tiraihi, T., & Ahmadiani, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8143-0 · Cited by 44
“…several sources including resting local OPCs outside (Wolswijk et al. 1990; Shi et al. 1998; Carroll et al. 1998; Jennings et al. 2002) or inside (Chang et al. 2002) the lesion and neural stem cells residing in the optic chiasm and nerves (Palmer et al. 1999), Schwann cells (Ghatak et al. 1973;…”
Backgroundde Jong, C. G. H. M., Gabius, H., & Baron, W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03327-7 · Cited by 44
Failure of Remyelination in the Nonhuman Primate Optic Nerve
Lachapelle, F., Bachelin, C., Moissonnier, P., Nait‐Oumesmar, B., Hidalgo, A., Fontaine, D., & Evercooren, A. B. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00521.x · Cited by 49
“Albeit LPC-induced lesions do not bare the inflammatory context of MS, both observations raise the possibility that such as in MS (10), improper balance of factors promoting or repressing activation of oligodendrocytes and their precursors may contribute to the failure in spontaneous CNS remyelination in this structur…”
BackgroundTcf7l2 is Tightly Controlled During Myelin Formation
Fu, H. Q., Kesari, S., & Cai, J. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9778-y · Cited by 50
“However, in some cases, pathological conditions can impede this process: progenitors are successfully recruited to the demyelinated area, but they fail to differentiate into mature oligodendrocytes (Chang et al. 2002; Kuhlmann et al. 2008).”
Myelin Repair: From Animal Models to Humans
Cayre, M., Falque, M., Mercier, O., Magalon, K., & Durbec, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.604865 · Cited by 48
Remyelination in multiple sclerosis: a new role for neurotrophins?
Althaus, H. H. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46026-3 · Cited by 49
Fox, M. A., Afshari, F. S., Alexander, J. K., Colello, R. J., & Fuss, B. (2005) · Glia · doi:10.1002/glia.20293 · Cited by 43
Paintlia, A. S., Paintlia, M. K., Singh, A. K., Orak, J. K., & Singh, I. (2010) · Glia · doi:10.1002/glia.21039 · Cited by 43
“In chronic lesions, axons are nonresponsive to OPCs (Chang et al., 2002; Dawson et al., 2000) due to the accumulation of inhibitory molecules or degraded myelin (Charles et al.”
BackgroundCid, C., Alvarez-Cermeño, J. C., Camafeita, E., Salinas, M., & Alcázar, A. (2003) · The FASEB Journal · doi:10.1096/fj.03-0606fje · Cited by 47
“These findings are in keeping with a report that describes a lower density of OPCs in MS lesions compared with nonlesion areas ( 46 ).”
ResultChari, D. M., Huang, W. L., & Blakemore, W. F. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10700 · Cited by 41
“…implications for understanding remyelination failure in MS and for attempts to correct the situation by transplantation of OPCs, because some areas of chronic demyelination have been shown to contain OPCs (Wolswijk, 1998; Chang et al., 2000) or dysfunctional oligodendrocytes (Chang et al., 2002).”
BackgroundImitola, J., Snyder, E. Y., & Khoury, S. J. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00021.2002 · Cited by 47
“It is likely that several complementary mechanisms contribute to the lack of remyelination in MS (49).”
BackgroundBrain lipid binding protein (FABP7) as modulator of astrocyte function
KIPP, M., CLARNER, T., GINGELE, S., POTT, F., AMOR, S., VAN DER VALK, P., & BEYER, C. (2011) · Physiological Research · doi:10.33549/physiolres.932168 · Cited by 42
Madadi, S., Pasbakhsh, P., Tahmasebi, F., Mortezaee, K., Khanehzad, M., Boroujeni, F. B., Noorzehi, G., & Kashani, I. R. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-0385-9 · Cited by 42
Poon, M. M., Lorrain, K. I., Stebbins, K. J., Edu, G. C., Broadhead, A. R., Lorenzana, A. O., Roppe, J. R., Baccei, J., Baccei, C. S., Chen, A. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2407974121 · Cited by 45
D’Aversa, T. G., Eugenin, E. A., & Berman, J. W. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21525 · Cited by 49
“…sclerosis (MS) is an immune-mediated disease of the CNS associated with demyelination of the white matter, perivascular inflammation, oligodendrocyte damage, axonal damage and/or loss, and breakdown of the blood–brain barrier (Trapp et al., 1998; Chang et al., 2002; Minagar and Alexander, 2003).”
BackgroundRegenerating CNS myelin: Emerging roles of regulatory T cells and CCN proteins
Gallardo, N. D. L. V., Dittmer, M., Dombrowski, Y., & Fitzgerald, D. C. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.11.024 · Cited by 42
“In demyelinating diseases such as MS, however, the regenerative capacity of oligodendrocytes declines with disease progression and can be lost entirely, leading to neurodegeneration and irreversible loss of function causing severe disability and morbidity for patients (Chang et al., 2002; Franklin and ffrench-Constant…”
BackgroundBain, J., Ziegler, A. N., Yang, Z., Levison, S. W., & Sen, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009567 · Cited by 50
“It is known that axonal loss will lead oligodendrocyte precursor death [55].”
BackgroundGrowth factor treatment of demyelinating disease: at last, a leap into the light
Ransohoff, R. M., Howe, C. L., & Rodriguez, M. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02321-9 · Cited by 45
Current concepts of the cellular and molecular pathophysiology of multiple sclerosis
Greenstein, J. I. (2007) · Developmental Neurobiology · doi:10.1002/dneu.20387 · Cited by 49
“, 2000, 2002) there is relatively ineffective remyelination of axons (Chang et al., 2002).”
Clinical implications of neuropathological findings in multiple sclerosis
Brück, W. (2005) · Journal of Neurology · doi:10.1007/s00415-005-2011-5 · Cited by 48
“However, recent studies have shown that premyelinating oligodendrocytes are present in regions devoid of remyelination, indicating that factors other than the presence of oligodendrocyte precursors affect remyelination in lesions [10, 43].”
BackgroundCaprariello, A. V., Batt, C. E., Zippe, I., Romito‐DiGiacomo, R. R., Karl, M. T., & Miller, R. H. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1706-15.2015 · Cited by 44
“…and/or microglia activation in the MBP-iCP9 mice (data not shown) may prime the system in a similar way, rendering susceptibility to a prolonged or exaggerated immune response and excessive myelin damage, even if potentially reparative OPCs are abundant in or around lesions (Chang et al., 2002).”
Backgroundde Jong, J. M., Wang, P., Oomkens, M., & Baron, W. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24582 · Cited by 45
Extrinsic Factors Driving Oligodendrocyte Lineage Cell Progression in CNS Development and Injury
Baydyuk, M., Morrison, V. E., Gross, P. S., & Huang, J. K. (2020) · Neurochemical Research · doi:10.1007/s11064-020-02967-7 · Cited by 45
Martínez‐Lozada, Z., Waggener, C. T., Kim, K., Zou, S., Knapp, P. E., Hayashi, Y., Ortega, A., & Fuss, B. (2014) · Glia · doi:10.1002/glia.22699 · Cited by 43
“In the major demyelinating disease in human, multiple sclerosis (MS), a block in oligodendrocyte differentiation is considered one of the main causes of inefficient remyelination and repair (Chang et al., 2002; Fancy et al., 2010; Kremer et al., 2011; Kuhlmann et al., 2008).”
BackgroundDefaux, A., Zurich, M.-G., Honegger, P., & Monnet-Tschudi, F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.053 · Cited by 40
Remyelination in the central nervous system
Franklin, R. J. M., Bodini, B., & Goldman, S. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041371 · Cited by 40
Sherafat, A., Pfeiffer, F., & Nishiyama, A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.721376 · Cited by 42
Fiore, F., Alhalaseh, K., Dereddi, R. R., Torres, F. B., Çoban, İ., Harb, A., & Agarwal, A. (2023) · Nature Communications · doi:10.1038/s41467-023-43920-w · Cited by 40
Lu, T.-Y., Hanumaihgari, P., Hsu, E. T., Agarwal, A., Kawaguchi, R., Calabresi, P. A., & Bergles, D. E. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01426-0 · Cited by 36
Disease-Responsive Neural Precursor Cells are Present in Multiple Sclerosis Lesions
Snethen, H., Love, S., & Scolding, N. J. (2008) · Regenerative Medicine · doi:10.2217/17460751.3.6.835 · Cited by 43
CNTF-Activated Astrocytes Release a Soluble Trophic Activity for Oligodendrocyte Progenitors
Albrecht, P. J., Enterline, J. C., Cromer, J. A., & Levison, S. W. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9151-6 · Cited by 47
Campath-1H Treatment of Multiple Sclerosis
Jones, J., & Coles, A. J. (2007) · Neurodegenerative Diseases · doi:10.1159/000109935 · Cited by 41
“Oligodendrocyte precursors are present in chronic MS lesions and remyelination is attempted [”
Baer, H. A. (2003) · Medical Anthropology Quarterly · doi:10.1525/maq.2003.17.2.233 · Cited by 41
The polarity protein Scribble regulates myelination and remyelination in the central nervous system
Jarjour, A. A., Boyd, A., Dow, L. E., Holloway, R. K., Goebbels, S., Humbert, P. O., Williams, A., & ffrench-Constant, C. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002107 · Cited by 39
“This can range from a complete failure of processes to contact axons to the presence of immature oligo-axonal contacts, indicating that these cells have differentiated, but have failed to successfully wrap axons [6].”
BackgroundWong, A. W., Giuffrida, L., Wood, R., Peckham, H., Gonsalvez, D., Murray, S. S., Hughes, R. A., & Xiao, J. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.10.002 · Cited by 39
Ding, Y., Zhang, R.-Y., He, B., Liu, Z., Zhang, K. K., Ruan, J., Ling, E., Wu, J., & Zeng, Y. (2015) · Scientific Reports · doi:10.1038/srep09133 · Cited by 39
“The rats were randomly divided into six groups (n 5 18 for each group, total 108 rats): (1) the sham group, received dorsal laminectomy and exposure of the dura only; (2) the PBS group, received PBS injection at the 4th day after EB injection; (3) the MSCs group, received MSCs graft at the 4th day after EB injection;…”
Methodvon Streitberg, A., Jäkel, S., Eugenin von Bernhardi, J., Straube, C., Buggenthin, F., Marr, C., & Dimou, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.662056 · Cited by 39
“However, even though NG2-glia density increases after TBI and AD, the number of progenitors is strongly reduced within chronic demyelinating lesions in MS (Chang et al., 2002; Sim et al., 2002).”
Background(Re)building the nervous system: A review of neuron–glia interactions from development to disease
Demmings, M. D., Chagas, L. D. S., Traetta, M. E., Rodrigues, R. S., Acutain, M. F., Barykin, E. P., Datusalia, A. K., German‐Castelan, L., Mattera, V. S., Mazengenya, P., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16258 · Cited by 49
Pouzol, L., Baumlin, N., Sassi, A., Tunis, M., Marrie, J., Vezzali, E., Farine, H., Mentzel, U., & Martinic, M. M. A. (2021) · The FASEB Journal · doi:10.1096/fj.202002465r · Cited by 41
Stem Cell Therapy for Ocular Disorders
Levin, L. A. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.621 · Cited by 38
“Oligodendrocyte progenitor cells can be identified in regions of active multiple sclerosis lesions but without apparent increase in numbers, as compared with findings in normal brain tissue.(46) At issue is whether the remyelinating cells are derived from a pool of glialrestricted progenitor cells or from multipotent…”
ResultRevisiting the astrocyte–oligodendrocyte relationship in the adult CNS
Carmen, J., Magnus, T., Cassiani‐Ingoni, R., Sherman, L. S., Rao, M. S., & Mattson, M. P. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.001 · Cited by 42
“As many glial progenitors are mobilized to the site of a demyelinating lesion (Chang et al., 2002), these cells might subsequently mature into astrocytes and further contribute to the prohibitive nature of the glial scar.”
BackgroundEndogenous remyelination is induced by transplant rejection in a viral model of multiple sclerosis
Hatch, M. N., Schaumburg, C. S., Lane, T. E., & Keirstead, H. S. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.05.002 · Cited by 39
“The underlying mechanisms governing the success of spontaneous remyelination are, however, complex and likely influenced by difficulties in recruiting proliferating OPCs to injured areas, inhibition of OPC maturation, and/or the failure of mature oligodendrocytes to generate myelin (Chang et al., 2002; Foote and Blake…”
BackgroundRemyelination and Restoration of Axonal Function by Glial Cell Transplantation
Duncan, I. D. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_7 · Cited by 39
The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis
Jadasz, J. J., Aigner, L., Rivera, F. J., & Küry, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1331-x · Cited by 43
“…to adult oligodendrogenesis, overall remyelination efficiency remains low and is further decreased with disease progression, possibly attributable to the presence of inhibitory factors (Chang et al. 2000, 2002; Kremer et al. 2011, 2009; Kuhlmann et al. 2008; Scolding et al. 1998; Wolswijk 1998).”
BackgroundFTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination
Kipp, M., & Amor, S. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512438723 · Cited by 37
Metcalfe, S. M., Strom, T. B., Williams, A., & Fahmy, T. M. (2015) · Nanobiomedicine · doi:10.5772/60622 · Cited by 40
“However, in MS, this repair process fails [29, 30].”
BackgroundIbudilast for the treatment of multiple sclerosis
Goodman, A. D., Gyang, T. V., & Smith, A. D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221924 · Cited by 39
Yazdi, A., Ghasemi‐Kasman, M., & Javan, M. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24509 · Cited by 38
Ma, Y., Jang, H., Chang, E. Y., Hiniker, A. O., Head, B. P., Lee, R. R., Corey‐Bloom, J., Bydder, G. M., & Du, J. (2020) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-541 · Cited by 40
Oligodendroglial Maturation Is Dependent on Intracellular Protein Shuttling
Göttle, P., Sabo, J. K., Heinen, A., Venables, G., Torres, K. J., Tzekova, N., Parras, C. M., Kremer, D., Hartung, H., Cate, H. S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1423-14.2015 · Cited by 39
“Several inhibitors associated with oligodendroglial differentiation have been identified and are supposed to constrain myelin repair in the adult CNS (Chang et al., 2002; Kuhlmann et al., 2008; Kremer et al., 2011).”
BackgroundZhang, J., Zhang, Y., Dutta, D. J., Argaw, A. T., Bonnamain, V., Seto, J., Braun, D. A., Zameer, A., Hayot, F., López, C. B., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004066 · Cited by 40
“functional recovery (4), but fails with disease progression (5).”
Vitamin D and remyelination in multiple sclerosis
Matías‐Guiu, J., Oreja‐Guevara, C., Matias-Guiu, J. A., & Gómez‐Pinedo, U. (2018) · Neurología (English Edition) · doi:10.1016/j.nrleng.2016.05.010 · Cited by 41
Nitric Oxide Synthase Expression and Nitric Oxide Toxicity in Oligodendrocytes
Boullerne, A. I., & Benjamins, J. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.967 · Cited by 38
Windener, F., Grewing, L., Thomas, C., Dorion, M.-F., Otteken, M., Kular, L., Jagodic, M., Antel, J., Albrecht, S., & Kuhlmann, T. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02733-x · Cited by 35
Barbierato, M., Facci, L., Marinelli, C., Zusso, M., Argentini, C., Skaper, S. D., & Giusti, P. (2015) · Scientific Reports · doi:10.1038/srep16676 · Cited by 37
The function of contactin‐2/TAG‐1 in oligodendrocytes in health and demyelinating pathology
Zoupi, L., Savvaki, M., Kalemaki, K., Kalafatakis, I., Sidiropoulou, K., & Karagogeos, D. (2017) · Glia · doi:10.1002/glia.23266 · Cited by 39
Approaches to Remyelination Therapies in Multiple Sclerosis
Wooliscroft, L., Silbermann, E., Cameron, M. H., & BOURDETTE, D. N. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0574-1 · Cited by 39
p57kip2 regulates glial fate decision in adult neural stem cells
Jadasz, J. J., Rivera, F. J., Taubert, A., Kandasamy, M., Sandner, B., Weidner, N., Aktaş, O., Hartung, H., Aigner, L., & Küry, P. (2012) · Development · doi:10.1242/dev.074518 · Cited by 39
“…remyelination efficiency remains low and is further decreased with disease progression, which is thought to be due to the presence of inhibitory factors (Scolding et al., 1998; Wolswijk, 1998; Chang et al., 2000; Chang et al., 2002; Kuhlmann et al., 2008; Kremer et al., 2009; Kremer et al., 2011).”
BackgroundRegulators of Oligodendrocyte Differentiation
Emery, B., & Wood, T. L. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041358 · Cited by 40
Rouillard, M. E., Hu, J., Sutter, P. A., Kim, H. W., Huang, J. K., & Crocker, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.833186 · Cited by 35
“This differentiation failure occurs even as OPCs populate the demyelinated lesions in the MS brain, indicating the presence of anti-differentiation factors or the loss of pro-differentiation factors (Wolswijk, 1998, 2002; Chang et al., 2002).”
BackgroundZveik, O., Fainstein, N., Rechtman, A., Haham, N., Ganz, T., Lavon, I., Brill, L., & Vaknin‐Dembinsky, A. (2022) · Glia · doi:10.1002/glia.24165 · Cited by 35
“It is suggested that differences in the OPC ability to differentiate may contribute to disease heterogeneity (Chang et al., 2002; Franklin, 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
BackgroundNicotinic acetylcholine receptors mediate donepezil‐induced oligodendrocyte differentiation
Imamura, O., Arai, M., Dateki, M., Ogata, T., Uchida, R., Tomoda, H., & Takishima, K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13294 · Cited by 36
“…they fail to differentiate into mature myelinforming oligodendrocytes and thus do not contribute to remyelination, most likely because of the presence of inhibitory factors within demyelinated lesions (Wolswijk 1998, 2002; Chang et al. 2000, 2002; Totoiu and Keirstead 2005; Kuhlmann et al. 2008).”
BackgroundFressinaud, C. (2004) · Glia · doi:10.1002/glia.20136 · Cited by 38
“…MS plaques, either secondary to demyelination, or directly induced by inflammatory cytokines (reviewed in Silber and Sharieff, 1999), the remyelination defect might also result from these lesions impairing myelin reconstruction (e.g., Guennoc et al., 2001; Chang et al., 2002; Charles et al., 2002).”
BackgroundInfluentialZeis, T., Howell, O. W., Reynolds, R., & Schaeren‐Wiemers, N. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.03.012 · Cited by 36
“, 2013), deficient OPC differentiation, proliferation or myelination (Franklin and Ffrench-Constant, 2008; Wolswijk, 1998) or compromised axons unable to support their remyelination (Chang et al., 2002).”
Liu, Z., Yan, M., Lei, W., Jiang, R., Dai, W., Chen, J., Wang, C., Li, L., Wu, M., Nian, X., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155096 · Cited by 37
Regeneration and repair in multiple sclerosis: The view of experimental pathology
Blakemore, W. F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.03.006 · Cited by 37
Shimizu, T., Durose, W. W., Li, J., Abe, M., Sakimura, K., Chetsawang, B., Sahara, Y., Tohyama, K., Tanaka, K. F., & Ikenaka, K. (2017) · Glia · doi:10.1002/glia.23134 · Cited by 35
“The presence of premyelinating oligodendrocytes in chronic demyelinated lesions is also associated with MS (Chang et al., 2002).”
BackgroundNeural stem cells in inflammatory CNS diseases: mechanisms and therapy
Magnus, T., & Rao, M. S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00357.x · Cited by 34
Létourneau, R., Rózniecki, J., Dimitriadou, V., & Theoharides, T. C. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.09.004 · Cited by 36
“In MS lesions, demyelination appears to be mediated by blood-borne mononuclear cells that penetrate the blood– brain barrier (BBB) at multiple sites (Raine, 1984; Chang et al., 2002; Paty and Arnold, 2002).”
Background?IV tubulin is selectively expressed by oligodendrocytes in the central nervous system
Terada, N., Kidd, G. J., Kinter, M. T., Bjartmar, C., Moran‐Jones, K., & Trapp, B. D. (2005) · Glia · doi:10.1002/glia.20175 · Cited by 36
“…oligodendrocytes that are in the premyelinating or early myelinating stages of differentiation is also important for studies of remyelination (Chang et al., 2000, 2002). bIV tubulin is expressed during early stages of myelination in rats, mice and human and in remyelinating oligodendrocytes…”
BackgroundSelf-citationMacchi, M., Magalon, K., Zimmer, C., Peeva, E., Waly, B. E., Brousse, B., Jäkel, S., Grobe, K., Kiefer, F., Williams, A., et al. (2020) · eLife · doi:10.7554/elife.51735 · Cited by 34
Macroglial diversity: white and grey areas and relevance to remyelination
Werkman, I. L., Lentferink, D. H., & Baron, W. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03586-9 · Cited by 35
Cellular senescence and failure of myelin repair in multiple sclerosis
Koutsoudaki, P. N., Papadopoulos, D., Passias, P.-G., Koutsoudaki, P., & Gorgoulis, V. G. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111366 · Cited by 33
Liu, H., Yang, X., Yang, J., Yuan, Y., Wang, Y., Zhang, R., Xiong, H., & Xu, Y. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.679413 · Cited by 35
Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans
Landolfo, E., Cutuli, D., Petrosini, L., & Caltagirone, C. (2022) · Biomolecules · doi:10.3390/biom12050667 · Cited by 37
O'Meara, R. W., Michalski, J.-P., Anderson, C., Bhanot, K., Rippstein, P., & Kothary, R. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5582-12.2013 · Cited by 33
“Understanding OL differentiation will be important for rectifying or circumventing myelinating diseases such as multiple sclerosis, where demyelinated lesions are characterized by stalled premyelinating OLs (Chang et al., 2002).”
BackgroundEvidence that nuclear factor IA inhibits repair after white matter injury
Fancy, S. P. J., Glasgow, S. M., Finley, M., Rowitch, D. H., & Deneen, B. (2012) · Annals of Neurology · doi:10.1002/ana.23590 · Cited by 34
“Clinically, these insults manifest themselves in neurological conditions such as cerebral palsy in infants and multiple sclerosis (MS) in adults.(1,4,5) Myelin sheaths are generated by OL progenitors (OLPs) that are recruited to developing axons or demyelinated lesions, where they differentiate in the immature brain (…”
BackgroundCNS axons retain their competence for myelination throughout life
Setzu, A., Ffrench‐Constant, C., & Franklin, R. J. M. (2004) · Glia · doi:10.1002/glia.10321 · Cited by 33
“It has been reported that chronic MS lesions contain pre-myelinating oligodendrocytes (Chang et al., 2002); our results suggest that the failure of these cells to progress to a myelinating phenotype is not a consequence of the length of time the axons have remained unmyelinated.”
BackgroundPoutiainen, P., Jaronen, M., Quintana, F. J., & Brownell, A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00085 · Cited by 37
“Remyelination is usually seen to occur in the early phases of the disease, whereas in the later phases it fails to recover the demyelinated areas leading to chronic demyelinated lesions (Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundHarnisch, K. J., Teuber‐Hanselmann, S., Macha, N., Mairinger, F. D., Fritsche, L., Soub, D., Meinl, E., & Junker, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010154 · Cited by 33
Wiendl, H., & Kieseier, B. C. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.689 · Cited by 35
Gender differences in the histopathology of MS?
Kuhlmann, T., GOLDSCHMIDT, T. J., Antel, J. P., Wegner, C., König, F. B., Metz, I., & Brück, W. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.07.014 · Cited by 38
Gillispie, G. J., Sah, E., Krishnamurthy, S., Ahmidouch, M. Y., Zhang, B., & Orr, M. E. (2021) · Life · doi:10.3390/life11020153 · Cited by 31
Knockdown of Lingo1b protein promotes myelination and oligodendrocyte differentiation in zebrafish
Wu, Y., & Hu, B. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.012 · Cited by 32
Neurodegeneration in multiple sclerosis: Defining the problem
Lisak, R. P. (2007) · Neurology · doi:10.1212/01.wnl.0000275227.74893.bd · Cited by 38
Jones, J., & Coles, A. J. (2009) · PubMed · Cited by 34
Ly, L., Barnett, M. H., Zheng, Y. Z., Gulati, T., Prineas, J. W., & Crossett, B. (2011) · Journal of Proteome Research · doi:10.1021/pr200672n · Cited by 34
Leonurine suppresses neuroinflammation through promoting oligodendrocyte maturation
Jin, M., Li, Q., Gu, Y., Wan, B., Huang, J., Xu, X., Huang, R., & Zhang, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14053 · Cited by 32
“In MS, myelin can dynamically be regenerated during the early stage, but the regeneration ability fails at the late stage.(7) Dampened OL differentiation may be the underlying mechanism, as abundant OPCs exist in chronic lesions of MS patients.”
BackgroundMany roles for oligodendrocyte precursor cells in physiology and pathology
Nishiyama, A., Serwanski, D. R., & Pfeiffer, F. (2021) · Neuropathology · doi:10.1111/neup.12732 · Cited by 32
Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration
Kalafatakis, I., Papagianni, F., Theodorakis, Κ., & Karagogeos, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054479 · Cited by 34
Endogenous or exogenous oligodendrocytes for remyelination
Blakemore, W. F., & Irvine, K. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.08.004 · Cited by 31
“More importantly, despite their presence within a lesion, the OPCs are unresponsive to the presence of demyelinated axons [2,5].”
Multiple Sclerosis: Does Nogo Play a Role?
Lee, J. Y., & Petratos, S. (2013) · The Neuroscientist · doi:10.1177/1073858413477207 · Cited by 32
Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation
Eixarch, H., Calvo‐Barreiro, L., Montalbán, X., & Espejo, C. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.019 · Cited by 35
Gene microarray analysis of multiple sclerosis lesions
Lock, C., & Heller, R. A. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.10.008 · Cited by 31
Raised venous pressure as a factor in multiple sclerosis
Talbert, D. G. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2007.10.009 · Cited by 31
“It has been observed that where oligodendrocytes do re-extend in a potential recovery phase they do not necessarily ‘recognise’ axons although passing in close proximity [ 25 ].”
BackgroundCRISPR-edited human ES-derived oligodendrocyte progenitor cells improve remyelination in rodents
Wagstaff, L. J., Bestard-Cuche, N., Kaczmarek, M., Fidanza, A., McNeil, L., Franklin, R. J. M., & Williams, A. C. (2024) · Nature Communications · doi:10.1038/s41467-024-52444-w · Cited by 30
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.